Showing 51-60 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Engineering fully vascularized SC-islets through endothelial integration and endocrine-vascular crosstalk | Boston Children’s Hospital | Juan Melero-Martin | Cures | 01-November-2025 to 31-October-2027 | $599.994,46 |
| Exploring Immunologic Mechanisms of Indirect (Encapsulated) Islet Graft Rejection | Johns Hopkins University | Joshua Doloff | Cures | 01-November-2025 to 31-October-2028 | $1.125.000,00 |
| Pseudohypoxia to improve SC-beta engraftment | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-October-2025 to 30-September-2027 | $600.000,00 |
| Hydrogels for Islet Engraftment in the Porcine Subcutaneous Space | Georgia Tech Research Corporation | Andres Garcia | Cures | 01-November-2025 to 31-October-2028 | $771.544,57 |
| Towards non-invasive imaging and improvement of islet engraftment via vascularization and oxygenation | Arizona Board of Regents, University of Arizona | Klearchos Papas | Cures | 01-October-2025 to 30-September-2027 | $897.151,29 |
| A Novel Ultra-Rapid Insulin | Wayne State University | Zhiqiang Cao | Improving Lives | 01-November-2025 to 31-October-2026 | $299.994,92 |
| ALIGN-T1D Start-Up Secretariat | Clinton Health Access Initiative (CHAI) | Colin Brown | Mission | 01-October-2025 to 31-March-2027 | $822.000,00 |
| Thermally responsive minimally invasive proangiogenic placeholder for cell transplantation for Type 1 Diabetes | University of Washington | Patrick Stayton | Cures | 01-November-2025 to 31-October-2028 | $894.965,96 |
| Clinical Translation of T-1123, an Ultra-rapid, Concentrated, Temperature stable Novel Insulin Analog | Invictus Therapeutics, LLC | Robyn Day | Improving Lives | 15-October-2025 to 31-May-2027 | $1.437.112,00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2025 to 30-September-2029 | $16.000.000,00 |